Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Biotech777on Feb 23, 2012 7:41pm

396 Views

Post# 19576672

RE: I am just putting it out there

Any well designed trial in addition to being double blinded and placebo controlled uses a core lab for exactly this reason. Not only to prevent premature analysis of the results but to ensure that whatever results are presented are reviewed by an independent group. I believe that is the role of the Cleveland Clinic or the trial arm C5 Research for this trial.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading